Klinische Studie NCT05086692 · Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-squamous

Klinische Studie NCT05086692 (Phase I/II) ist «aktiv (nicht rekrutierend)» auf ClinicalTrials.gov.

Erkrankung: Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-squamous · Registrierte Interventionen: MDNA11, Pembrolizumab (KEYTRUDA®) · Erfasste Daten (Quelle): 2021-08-27, 2028-10-20, 2021-10-21, 2026-10-30.

Studienzusammenfassung (Quelle: ClinicalTrials.gov, Originaltext auf Englisch):

This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

Quelle: https://clinicaltrials.gov/study/NCT05086692